CRWV vs PFE: Which Is the Better Buy?
Side-by-side comparison of CoreWeave, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-08-06.
CoreWeave, Inc. · Technology
$89.89
+24.6% upside to fair value
Med Conviction
Grade C+
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
CRWV has more upside to fair value
(+24.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWV |
PFE |
| Current Price |
$89.89 |
$25.22 |
| Fair Value Estimate |
$112.00 |
$25.92 |
| Upside to Fair Value |
+24.6%
|
+2.8%
|
| Market Cap |
$49.0B |
$143.7B |
| Forward P/E |
—
|
19.2x
|
| EV / EBITDA |
26.6x
|
12.3x
|
| Price / Sales |
7.9x
|
2.3x
|
| Price / FCF |
—
|
15.2x
|
| Revenue Growth YoY |
+111.6%
|
+5.4%
|
| Gross Margin |
69.4%
|
69.3%
|
| Operating Margin |
-2.6%
|
23.4%
|
| Return on Equity |
-33.5%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
-21.6%
|
6.6%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
CoreWeave is the leading neocloud, a GPU-specialized cloud infrastructure provider built to serve the compute-hungry demands of generative AI training and inference. Since its March 2025 IPO, revenue has scaled roughly 112% year over year to $2.08 billion in the first quarter of 2026, backed by a $99.4 billion contracted revenue backlog and marquee agreements with Microsoft, OpenAI, Meta, Anthrop…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
CRWV |
PFE |
| Zone Low |
$84.00 |
$19.44 |
| Zone High |
$95.00 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|